Comparison

Delvant vs Putnam Associates

Putnam Associates is the boutique we benchmark hardest against. Senior-led teams, custom-scoped engagements, strong citation discipline. Delvant does not try to be a cheaper Putnam. The two are different shapes of work, used by different buyers at different decision points. This page lays out where each fits.

Last updated 2026-05-16. Snapshot based on public information; refreshed quarterly.

What each one is

Putnam Associates is a boutique life-sciences strategy consultancy founded in 1988, focused on commercial strategy, lifecycle management, M&A and licensing diligence, and market access for biopharma clients. Teams are senior-heavy by design (lower partner-to-associate ratio than IQVIA Consulting or McKinsey LSP), engagements typically run 6-12 weeks with integrated primary research (KOL interviews, payer interviews, sometimes patient research), and deliverables read as recommendation-driven strategic documents. Pricing is not publicly disclosed; boutique life-sciences strategy engagements of this shape typically land between EUR 100K and EUR 500K, scoped per project. Acquired by Inflexion Private Equity in 2021.

Delvant is a bounded custom-intelligence service. Each engagement starts from one or two specific questions a buyer cannot answer with a templated report, scopes the comparator set, runs a fresh search against locked anchor sources (ClinicalTrials.gov, EMA, FDA, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO), tags every claim by provenance tier (Sourced, Inferred, Opinion, Hedged), and ships a 10-30 page deliverable in 5-15 business days. Tier 1 briefs start at EUR 3,500. Tier 2 strategic dossiers run EUR 12,000-35,000.

Side-by-side

Dimension Putnam Associates Delvant
Product shape Senior-led strategy engagement. Recommendation-driven. Steering committee + interim readouts + final. Bounded custom-scoped deliverable. Intelligence-driven (facts + provenance), recommendation kept narrow and explicit.
Therapeutic area scope Broad biopharma coverage. Oncology, immunology, rare disease, neuroscience, cardiometabolic, infectious disease, gene/cell therapy. Narrow. Core: rare hematology, immune cytopenias (ITP, AIHA, HDFN), plasma-derived therapeutics. Adjacent: rare oncology, IgG autoimmune, transplant.
Citation discipline Strong by boutique standards. Methodology and source lists transparent in deliverables. Per-claim tier tags (Sourced / Inferred / Opinion / Hedged) visible inline on every assertion. Every Sourced claim re-verified at the cited URL during Gate A pass.
Primary research + KOL access Core capability. KOL panels, payer interviews, and primary research integrated into nearly every engagement. Optional. T2 includes a small KOL probe set (3-6 interviews) when scoped; T1 is desk-research only. Delvant is not a primary-research shop.
Output orientation Recommendation-led. The deliverable tells you what to do. Intelligence-led. The deliverable tells you what is verifiably true, what is inferred, what is opinion. Recommendations are deliberately narrow and tagged.
Turnaround 6-12 weeks typical for a strategy engagement, with steering rhythm. 5 business days (T1). 10-15 business days (T2). Fixed schedule, no rush-fee compression.
Indicative price (public) Not publicly disclosed. Boutique life-sciences strategy engagements of this shape typically range from EUR 100K to EUR 500K, scoped per project. From EUR 3,500 (T1, 1 question, 10-15 pages). EUR 12,000-35,000 (T2, 2-3 questions, 20-30 pages).
Team shape Senior consultants + small associate bench. Partner present throughout engagement. Single accountable owner per engagement (founder-led at current stage). External peer pass + LLM-council adversarial review built into Gates A/B/C.
AI methodology AI use disclosed at engagement scoping. Per-engagement varies. AI-assisted retrieval and synthesis under documented human oversight. Gate A re-verifies every Sourced claim; Gate B runs LLM-council adversarial review. EU AI Act Article 4 deployer posture disclosed.
Public sample deliverables Published case studies and report excerpts on company site. Full T2 demonstrator (ITP TPO-RA vs FcRn) published openly with per-claim provenance tagging visible. T1/T2/T3/T4 deck-format previews available.
Buyer fit Biopharma commercial leadership, BD, lifecycle management, market access leads. Decisions tied to launch, in-licensing, or portfolio shape. Medical affairs, BD search-and-evaluation, small-biotech CMOs, life-sciences analysts who need a single sharp comparator answer with audit-grade citation, fast.

When to pick which

Putnam Associates is a better fit when

  • You need a recommendation, not just intelligence. The decision must come signed-off by the consultant.
  • Primary research is essential (KOL panels, payer interviews, patient research run by the engagement team).
  • The decision is commercial leadership, lifecycle, or BD-licensing scale: budget six figures, timeline 6-12 weeks.
  • You want partner-level oversight present every week of the engagement.
  • The question genuinely needs a full strategy framework, not a focused comparator answer.

Delvant is a better fit when

  • You have one or two precise comparator questions and need an audit-grade answer in days, not months.
  • You need every claim tier-tagged and citation-verified before sharing internally or with a committee.
  • The decision is medical-affairs or BD search-and-evaluation, not full-launch or M&A scale.
  • Your TA is in our core: rare hematology, immune cytopenias, plasma-derived, adjacent rare oncology and IgG autoimmune.
  • The question budget sits between EUR 3,500 and EUR 35,000, not between EUR 100K and EUR 500K.

Where Delvant deliberately does not compete

Delvant is not a strategy consultancy. If your question requires 6-12 weeks of senior-led advisory time, integrated primary research, a steering committee, and a signed recommendation, you should commission Putnam Associates (or Trinity, L.E.K. Life Sciences, Health Advances, ZS, IQVIA Consulting). Delvant does not replace that work; it solves a different problem.

Delvant is also not a database. There is no log-in, no live pipeline tracker, no proprietary claims or EMR data. If your team needs a standing query layer across thousands of assets every week, a syndicated stack like Citeline, GlobalData, Evaluate, or Clarivate Cortellis is the right shape of tool. Delvant covers the gap between those two extremes: bounded custom work at 5-15 business day turnaround, EUR 3,500-35,000, narrow TA, audit-grade citation.

Honest note on positioning. Of the boutiques we benchmark, Putnam Associates has the cleanest citation hygiene and the closest shape-fit to what Delvant publishes. We are not a cheaper Putnam. We are not a faster Putnam either, in the sense that fast does not mean better for the questions Putnam is hired to answer. We are useful for the questions a medical affairs or BD team has that do not yet justify a EUR 100K-500K engagement, but still need an audit-grade answer they can defend internally. When a question outgrows that frame, we say so and point clients toward Putnam or peers.

Other comparisons

Side-by-side fit-call pages for adjacent providers.

Delvant vs GlobalData: syndicated pharma database subscriptions vs bounded custom intelligence.

Delvant vs Citeline: enterprise syndicated pharma stack vs commissioned engagement.

Delvant vs IQVIA Consulting: multi-month strategy consulting vs 5-15 day commissioned single-question deliverable.

Delvant vs Lucid Bio: bespoke biotech intelligence vs bounded custom clinical intelligence.

Not sure which fits your question?

30-minute scoping call. We will tell you whether a Delvant T1 or T2 fits, or whether the question genuinely needs a boutique strategy engagement. Honest fit calls only.

Book a scoping call See engagement tiers